- Gear Up (Helmets Included) for a Safe Bike Season
- It’s National Nutrition Month: Here’s Tips to Eating Right
- COVID Origins Tied to Raccoon Dogs Sold at Wuhan Market
- Tick-Borne Illness Babesiosis Spreads to New U.S. States
- AHA News: These Healthy Habits Might Also Lead to a Happier Life
- Pets in the Bedroom? Your Sleep Might Suffer, Study Finds
- Chlamydia: What It Is, Symptoms, Treatment & More
- In Mouse Study, Scientists Use Gene Editing to Reverse a Major Cause of Blindness
- Sanofi Follows Lilly, Novo Nordisk in Cutting Insulin Prices
- How Metal Implants Could Mess Up Your Skin
Donor-Lung Preservation Device Approved

The XVIVO Perfusion System has been approved by the U.S. Food and Drug Administration to help preserve donor lungs that ultimately may be used for transplant, the agency said Tuesday in a news release.
The device is expected to be used to preserve lungs that initially may not meet transplant criteria but could be used after doctors have been given more time to evaluate the organ, the agency said.
Transplant is an option for people with severe lung problems, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or idiopathic pulmonary fibrosis, the FDA said.
The just-approved device can be used to warm donor lungs to the appropriate temperature and flush lung tissue with a sterile solution called STEEN, the agency explained. The device also provides oxygen to the donor organ’s cells for up to four hours.
Device manufacturer XVIVO Perfusion, based in Englewood, Colo., will be required to conduct a post-approval study of the device’s long-term effects and any adverse reactions, the FDA said.
More information
Visit the FDA for more about this approval.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.